News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
AD HOC NEWS Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Sanofi Winthrop Industrie Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the …
Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%Sanofi and UNICEF have partnered to improve childhood immunisation access in three Eastern Cape districts in South Africa, targeting children who have not received or completed routine vaccinations. The "Immunisation for Every Child" program, running from July 2026 to March 2027, will equip health …
Sanofi is reorganizing its Executive Committee, effective September 1, 2026, to expand the finance function's responsibilities and consolidate its senior leadership. The finance division will now oversee enterprise business services, Global Partnering, Business Development, and M&A, with François Roger remaining as EVP of Finance. …
The Manufacturers Life Insurance Company significantly reduced its stake in Sanofi by 58.9% in the first quarter of 2026, selling over 33,000 shares. Despite this, other institutional investors like Assetmark, QRG Capital Management, and Evergreen Capital Management increased their holdings in the pharmaceutical company. …
Analysts have cut Sanofi's average 12-month price target from $50.6 to $50, with individual forecasts ranging from $45 to $57 per share. Based on the Aug. 7 closing price, this new target suggests a potential upside of approximately 15%. The consensus rating from seven …
It was reported on July 24 that Sanofi (NASDAQ:SNY) shares underperformed in European trading following the company's decision to drop the clinical development of its eczema candidate, amlitelimab, for moderate-to-severe atopic dermatitis. Rather than a fundamental breakdown, the move reflects an aggressive R&D pipeline …
Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%Sanofi received European Commission approval to expand the MenQuadfi meningococcal vaccine's use to infants as young as six weeks old, covering a high-risk population. Despite this and a recent share buyback, Sanofi's stock performance has been subdued. The company's valuation narrative suggests it is …
The European Commission has approved Sanofi's MenQuadfi vaccine for use in infants as young as 6 weeks, expanding protection against invasive meningococcal disease. This decision is significant for hearing healthcare professionals, as the disease is a leading cause of acquired sensorineural hearing loss in …
The NAACP and Sanofi have launched an interactive health equity map called "Black Communities' Health: In Plain Sight." This tool uses data from nearly 23,000 residents across 47 states, D.C., and Puerto Rico to highlight health disparities at the ZIP-code level, focusing on access …
Sanofi has suspended a phase 2 trial of its monoclonal antibody SAR445399 for non-cystic fibrosis bronchiectasis. The decision stems from a company-wide portfolio review under new CEO Belén Garijo, not safety concerns. This pause follows other recent pipeline adjustments as Sanofi reassesses its late-stage …
Former Sanofi, CVS Health, and McKesson Executive Improve Specialty Drug Access, Affordability and Patient Support NEW YORK, August 06, 2026--(BUSINESS WIRE)--Leap, the healthcare company making specialty medicine more affordable and easier to access, today announced the appointment of Christine Hummel as Senior Vice President …
Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%Sanofi has paused a Phase 2 study for an investigational antibody, SAR445399, in non-cystic fibrosis bronchiectasis as part of new CEO Belén Garijo’s "rigorous portfolio prioritization" process. This decision is based on strategic business reasons rather than the asset's safety or efficacy. The company …
Sanofi has been asked by the National Advertising Division (NAD) to alter or remove specific advertising claims for its drug Dupixent, following a challenge by Galderma. This development is part of an ongoing advertising dispute between the two pharmaceutical companies, which are competing for …
Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework Improved GAAP Combined R&D and SG&A expense guidance by $10 million at mid-point Sanofi confirmed with Novavax that they are in advanced discussions with regulators regarding …
Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%Antipodes Partners published its "Antipodes Global Strategy" second-quarter 2026 investor letter, highlighting the key performance stocks, portfolio changes, and the market outlook. A copy of the letter can be downloaded here. The second quarter of 2026 delivered one of the strongest equity market recoveries …
Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%Expedition Therapeutics, backed by Sanofi, has raised an oversubscribed $115 million in Series B financing to propel its lead DPP1 inhibitor, EXPD-101, through phase 2 trials for chronic obstructive pulmonary disease (COPD). This funding follows a $165 million Series A in October 2025 and …
Sanofi has halted a phase 2 trial for SAR445399, a monoclonal antibody for non-cystic fibrosis bronchiectasis, citing "strategic business reasons" following a company-wide portfolio review. This decision comes amidst a challenging period for Sanofi, marked by recent trial failures and the new CEO's efforts …
Sanofi's MenQuadfi vaccine has
Nurix Therapeutics, Inc. Oral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has earned approximately $139 million to date under its collaboration with Sanofi and remains eligible to receive approximately $453 million in future milestones associated with the STAT6 program, …
Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%[Sanofi building on New York Ave in Framingham, MA, USA] JHVEPhoto Sanofi (SNY [https://seekingalpha.com/symbol/SNY]) received [https://seekingalpha.com/pr/20605048-press-release-sanofi-s-menquadfi-approved-in-the-eu-for-use-in-infants-from-age-six-weeks] European Commission approval to expand MenQuadfi’s indication to infants aged six weeks and older for protection against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W …
Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%The European Commission has approved an extension of the indication for Sanofi's MenQuadfi vaccine to include infants from six weeks of age, protecting against invasive meningococcal disease caused by serogroups A, C, W, and Y. This expanded approval, supported by the MET58 pivotal study, …
Search by ticker symbol or company name and select a result to open its chart.